Analyst Recommendations
Here’s a summary of ratings for TriSalus Life Sciences and its competitors from MarketBeat.com.
| Sell | Hold | Buy | Strong Buy | Rating Score | |
| TriSalus Life Sciences | 0 | 0 | 4 | 0 | 3.00 |
| Competitors | 1662 | 4404 | 8408 | 251 | 2.49 |
TriSalus has a target price of $12.50, suggesting a 198.33% potential increase, compared to 17.60% for other surgical and medical instrument companies.
Volatility & Risk
TriSalus has a beta of 0.47, indicating it’s 53% less volatile than the S&P 500, while its competitors have a beta of 0.53.
Valuation and Earnings
| Gross Revenue | Net Income | P/E Ratio | |
| TriSalus Life Sciences | $24.74 million | -$59.04 million | -1.68 |
| Competitors | $875.84 million | $47.94 million | -1.12 |
TriSalus has lower revenue and earnings than its competitors but trades at a lower P/E ratio, suggesting it may be more affordable.
Profitability
| Net Margins | Return on Equity | Return on Assets | |
| TriSalus Life Sciences | -219.71% | N/A | -192.99% |
| Competitors | -575.50% | -141.13% | -25.81% |
Insider & Institutional Ownership
2.6% of TriSalus’ shares are held by institutions, compared to 47.4% industry-wide. 76.2% of shares are held by company insiders, significantly higher than the industry average of 15.9%.
Summary
TriSalus falls short against its competitors in 7 of 13 factors measured.
Company Profile
TriSalus Life Sciences, Inc. develops drug delivery technologies for treating liver and pancreatic cancer. Founded in 2009, it’s based in Westminster, Colorado.
Receive News & Ratings for TriSalus Life Sciences Daily – Enter your email below for a daily summary of news and ratings. MarketBeat.com’s FREE daily email newsletter.
`
